Alemtuzumab Versus Thymoglobulin Induction Therapy in Kidney and Pancreas Transplantation.

Trial Profile

Alemtuzumab Versus Thymoglobulin Induction Therapy in Kidney and Pancreas Transplantation.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 02 May 2016

At a glance

  • Drugs Alemtuzumab (Primary) ; Antithymocyte globulin (Primary)
  • Indications Kidney-pancreas transplant rejection; Pancreas transplant rejection; Renal transplant rejection
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 26 Apr 2016 Planned End Date changed from 1 Jun 2015 to 1 Jun 2017.
    • 23 Oct 2011 Results assessing the rates of infectious complications presented at the 49th Annual Meeting of the Infectious Diseases Society of America.
    • 15 Aug 2010 Results presented at the 23rd International Congress of the Transplantation Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top